# Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

> **NCT02005289** · PHASE2 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 41 (actual)

## Conditions studied

- Contiguous Stage II Small Lymphocytic Lymphoma
- Noncontiguous Stage II Small Lymphocytic Lymphoma
- Prolymphocytic Leukemia
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Stage I Chronic Lymphocytic Leukemia
- Stage I Small Lymphocytic Lymphoma
- Stage II Chronic Lymphocytic Leukemia
- Stage III Chronic Lymphocytic Leukemia
- Stage III Small Lymphocytic Lymphoma
- Stage IV Chronic Lymphocytic Leukemia
- Stage IV Small Lymphocytic Lymphoma

## Interventions

- **BIOLOGICAL:** MOR00208
- **DRUG:** lenalidomide
- **OTHER:** Correlative Studies

## Key facts

- **NCT ID:** NCT02005289
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-17
- **Primary completion:** 2025-05-20
- **Final completion:** 2025-05-20
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02005289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02005289, "Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02005289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*